Progesterone limits the tumor-promoting effects of the beta-subunit of human chorionic gonadotropin via non-nuclear receptors

Sarkar, Moumita; Sharma, Harsh; Singh, Parminder; Ranu, Ranbala; Sharma, Ravi Datta; Agrawal, Usha; Pal, Rahul

doi:10.1016/j.isci.2022.104527

Cited by 2 publications

(6 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As described in Sarkar et al. 1 the signaling and cytopathic action of progesterone in this model appears to be mediated by membrane (non-classical) receptors. Interestingly (and as also mentioned in Sarkar et al.…”

Section: Limitationsmentioning

confidence: 64%

“…Confirm the efficacy of the surgery by assessing serum prolactin levels, as described in Sarkar et al. 1 …”

Section: Step-by-step Methods Detailsmentioning

confidence: 99%

“… Confirm the efficacy of the surgery by assessing serum prolactin levels, as described in Sarkar et al. 1 After 14 days of surgery, subcutaneously inject 40,000 LLC1 tumor cells (suspended in serum-free DMEM) on the dorsal side, using a 26G needle. Note: Shave the dorsal side of the animal a day before tumor cell implantation; carefully inspect the area to ensure absence of skin allergy or local inflammation due to shaving.…”

Section: Step-by-step Methods Detailsmentioning

confidence: 99%

“…Though ELISA-based assays also can be employed for the detection of beta-hCG in serum, a sensitive and specific radio-immunoassay was employed in these studies, the protocol for which is described in Sarkar et al. 1 …”

Section: Before You Beginmentioning

confidence: 99%

“…We have demonstrated the effect of steroids in LLC1 tumor cells in culture for a maximum of 48 h (Sarkar et al. 1 ). MTT experiments (in 96-well plates) designed with similar timelines work best when cell numbers are kept lower than 10 4 per well.…”

Section: Expected Outcomesmentioning

confidence: 99%

See 4 more Smart Citations

Workflow in transgenic mice for the study of specific cancers associated with the post-menopausal state

Sarkar¹,

Singh²,

Pal³

2023

STAR Protocols

Self Cite

View full text Add to dashboard Cite

Section: Limitationsmentioning

confidence: 64%

“…Confirm the efficacy of the surgery by assessing serum prolactin levels, as described in Sarkar et al. 1 …”

Section: Step-by-step Methods Detailsmentioning

confidence: 99%

Section: Step-by-step Methods Detailsmentioning

confidence: 99%

Section: Before You Beginmentioning

confidence: 99%

Section: Expected Outcomesmentioning

confidence: 99%

See 3 more Smart Citations

Workflow in transgenic mice for the study of specific cancers associated with the post-menopausal state

Sarkar¹,

Singh²,

Pal³

2023

STAR Protocols

Self Cite

View full text Add to dashboard Cite

Progesterone boosts abiraterone-driven target and NK cell therapies against glioblastoma

Chen,

Lin,

Chiang

et al. 2024

J Exp Clin Cancer Res

View full text Add to dashboard Cite

Introduction Glioblastoma (GBM) poses a significant challenge in oncology, with median survival times barely extending beyond a year due to resistance to standard therapies like temozolomide (TMZ). This study introduces a novel therapeutic strategy combining progesterone (Prog) and abiraterone (Abi) aimed at enhancing GBM treatment efficacy by modulating the tumor microenvironment and augmenting NK cell-mediated immunity. Methods We employed in vitro and in vivo GBM models to assess the effects of Prog and Abi on cell viability, proliferation, apoptosis, and the immune microenvironment. Techniques included cell viability assays, Glo-caspase 3/7 apoptosis assays, RNA-seq and qPCR for gene expression, Seahorse analysis for mitochondrial function, HPLC-MS for metabolomics analysis, and immune analysis by flow cytometry to quantify NK cell infiltration. Results Prog significantly reduced the IC50 of Abi in TMZ-resistant GBM cell, suggesting the enhanced cytotoxicity. Treatment induced greater apoptosis than either agent alone, suppressed tumor growth, and prolonged survival in mouse models. Notably, there was an increase in CD3−/CD19−/CD56+/NK1.1+ NK cell infiltration in treated tumors, indicating a shift towards an anti-tumor immune microenvironment. The combination therapy also resulted in a reduction of MGMT expression and a suppression of mitochondrial respiration and glycolysis in GBM cells. Conclusion The combination of Prog and Abi represents a promising therapeutic approach for GBM, showing potential in suppressing tumor growth, extending survival, and modulating the immune microenvironment. These findings warrant further exploration into the clinical applicability of this strategy to improve outcomes for GBM patients.

show abstract

Progesterone limits the tumor-promoting effects of the beta-subunit of human chorionic gonadotropin via non-nuclear receptors

Cited by 2 publications

References 66 publications

Workflow in transgenic mice for the study of specific cancers associated with the post-menopausal state

Workflow in transgenic mice for the study of specific cancers associated with the post-menopausal state

Progesterone boosts abiraterone-driven target and NK cell therapies against glioblastoma

Contact Info

Product

Resources

About